Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Anthony E. Lang, Alberto J. Espay
Movement Disorders (2018) Vol. 33, Iss. 5, pp. 660-677
Open Access | Times Cited: 319

Showing 1-25 of 319 citing articles:

LRRK2 in Parkinson disease: challenges of clinical trials
Eduardo Tolosa, Miquel Vila, Christine Klein, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 2, pp. 97-107
Closed Access | Times Cited: 371
New insights into the complex role of mitochondria in Parkinson’s disease
Anne Grünewald, Kishore R. Kumar, Carolyn M. Sue
Progress in Neurobiology (2018) Vol. 177, pp. 73-93
Open Access | Times Cited: 332
Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis
Michaela Johnson, Benjamin Stecher, Viviane Labrie, et al.
Trends in Neurosciences (2018) Vol. 42, Iss. 1, pp. 4-13
Open Access | Times Cited: 268
Trial of Prasinezumab in Early-Stage Parkinson’s Disease
Gennaro Pagano, Kirsten I. Taylor, Judith Anzures‐Cabrera, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 5, pp. 421-432
Open Access | Times Cited: 261
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Ahmad Elkouzi, Vinata Vedam‐Mai, Robert S. Eisinger, et al.
Nature Reviews Neurology (2019) Vol. 15, Iss. 4, pp. 204-223
Open Access | Times Cited: 252
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin, Rossella Medori, Robert A. Hauser, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 11, pp. 804-822
Closed Access | Times Cited: 240
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
Rob M.A. de Bie, Carl E Clarke, Alberto J. Espay, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 5, pp. 452-461
Closed Access | Times Cited: 157
Doença de Parkinson: Revisão Clínica e Atualização
Verónica Cabreira, João Massano
Acta Médica Portuguesa (2019) Vol. 32, Iss. 10, pp. 661-670
Open Access | Times Cited: 154
Isradipine Versus Placebo in Early Parkinson Disease

Annals of Internal Medicine (2020) Vol. 172, Iss. 9, pp. 591-598
Open Access | Times Cited: 152
Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy
Xiaoyan Gao, Tuo Yang, Ying Gu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 74
Multifunctional Nanotheranostics for Overcoming the Blood–Brain Barrier
M H Miran Beygi, Fatemeh Oroojalian, Soheil Azizi‐Arani, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 19
Closed Access | Times Cited: 22
Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives
Ramyar Rahimi Darehbagh, Seyedeh Asrin Seyedoshohadaei, Rojin Ramezani, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 20
Neuroimaging of Parkinson's disease by quantitative susceptibility mapping
Xiaojun Guan, Marta Lancione, Scott Ayton, et al.
NeuroImage (2024) Vol. 289, pp. 120547-120547
Open Access | Times Cited: 17
Mobilizing Parkinson’s Disease: The Future of Exercise
Terry D. Ellis, Lynn Rochester
Journal of Parkinson s Disease (2018) Vol. 8, Iss. s1, pp. S95-S100
Open Access | Times Cited: 144
A Cortical Pathogenic Theory of Parkinson’s Disease
Guglielmo Foffani, José Á. Obeso
Neuron (2018) Vol. 99, Iss. 6, pp. 1116-1128
Open Access | Times Cited: 137
An update on best practice of deep brain stimulation in Parkinson’s disease
Christian J. Hartmann, Sabine Fliegen, Stefan Jun Groiss, et al.
Therapeutic Advances in Neurological Disorders (2019) Vol. 12
Open Access | Times Cited: 128
Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
Roberto Cilia, Emanuele Cereda, Albert Akpalu, et al.
Brain (2020) Vol. 143, Iss. 8, pp. 2490-2501
Open Access | Times Cited: 123
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
Lana M. Chahine, Thomas G. Beach, Michael C. Brumm, et al.
Neurology (2020) Vol. 95, Iss. 9
Open Access | Times Cited: 123
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing, Sue Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 3, pp. 757-774
Open Access | Times Cited: 119
Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence
Tommaso Schirinzi, Giuseppina Martella, Paola Imbriani, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 116
Disease modification and biomarker development in Parkinson disease
Alberto J. Espay, Lorraine V. Kalia, Ziv Gan‐Or, et al.
Neurology (2020) Vol. 94, Iss. 11, pp. 481-494
Open Access | Times Cited: 115
Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
Miquel Vila
Movement Disorders (2019) Vol. 34, Iss. 10, pp. 1440-1451
Open Access | Times Cited: 114
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
Tanya Simuni, Brian Fiske, Kalpana Merchant, et al.
JAMA Neurology (2020) Vol. 78, Iss. 3, pp. 312-312
Open Access | Times Cited: 111
Understanding the Links Between Cardiovascular Disease and Parkinson's Disease
Judy Potashkin, Xuemei Huang, Claudia Becker, et al.
Movement Disorders (2019) Vol. 35, Iss. 1, pp. 55-74
Open Access | Times Cited: 106
The gut microbiome in Parkinson's disease: A culprit or a bystander?
Ali Keshavarzian, Phillip A. Engen, Salvatore Bonvegna, et al.
Progress in brain research (2020), pp. 357-450
Closed Access | Times Cited: 85
Page 1 - Next Page

Scroll to top